8 analysts have expressed a variety of opinions on Inari Medical NARI over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 0 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 3 | 0 | 2 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $66.75, along with a high estimate of $75.00 and a low estimate of $52.00. This current average has decreased by 8.06% from the previous average price target of $72.60.
Investigating Analyst Ratings: An Elaborate Study
The perception of Inari Medical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| William Plovanic | Canaccord Genuity | Maintains | Buy | $75.00 | $75.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $52.00 | $61.00 |
| Mike Matson | Needham | Maintains | Buy | $72.00 | - |
| Mike Matson | Needham | Maintains | Buy | $72.00 | - |
| Richard Newitter | Truist Securities | Lowers | Hold | $61.00 | $63.00 |
| Adam Maeder | Piper Sandler | Lowers | Neutral | $55.00 | $85.00 |
| William Plovanic | Canaccord Genuity | Lowers | Buy | $75.00 | $79.00 |
| Mike Matson | Needham | Announces | Buy | $72.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inari Medical. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Inari Medical compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Inari Medical's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Inari Medical's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Inari Medical analyst ratings.
Get to Know Inari Medical Better
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Inari Medical's Economic Impact: An Analysis
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Inari Medical displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 22.57%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -3.53%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Inari Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.02%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Inari Medical's ROA stands out, surpassing industry averages. With an impressive ROA of -0.76%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.07.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
